{"id":52583,"date":"2024-10-29T12:49:57","date_gmt":"2024-10-29T10:49:57","guid":{"rendered":"https:\/\/www.fyb.de\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/"},"modified":"2024-10-29T12:49:57","modified_gmt":"2024-10-29T10:49:57","slug":"armira-acquires-minority-stake-in-pharos-together-with-viessmann","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/","title":{"rendered":"Armira acquires minority stake in PharOS together with Viessmann"},"content":{"rendered":"
\n
\n
\n

Munich\/ Batten\u00adberg (Eder) \u2014 Viess\u00admann Gene\u00adra\u00adti\u00adons Group (\u201cViess\u00admann\u201d), a leading family-owned company with a 107-year history, and the invest\u00adment holding Armira have acqui\u00adred a signi\u00adfi\u00adcant mino\u00adrity stake in the Euro\u00adpean phar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adper and manu\u00adfac\u00adtu\u00adrer PharOS as part of a consor\u00adtium. The invest\u00adment under\u00adlines Viess\u00adman\u00adn\u2019s stra\u00adte\u00adgic focus on long-term value crea\u00adtion in indus\u00adtries that are criti\u00adcal to the well-being of future gene\u00adra\u00adti\u00adons. PharOS ensu\u00adres access to high-quality and afforda\u00adble health\u00adcare in Europe. The Viess\u00admann holding company now holds around 27 percent of the shares in the gene\u00adrics manu\u00adfac\u00adtu\u00adrer, with Armira holding a further 13 percent. PharOS<\/strong> is a leading phar\u00admaceu\u00adti\u00adcal company that deve\u00adlops, produ\u00adces and supplies gene\u00adrics, over-the-coun\u00adter medi\u00adci\u00adnes and value-added medi\u00adci\u00adnes. The company, based in Meta\u00admor\u00adfosi near Athens, specia\u00adli\u00adzes in parti\u00adcu\u00adlar in diffi\u00adcult-to-produce gene\u00adrics in criti\u00adcal treat\u00adment areas. These include onco\u00adlogy and drugs for neuro\u00adlo\u00adgi\u00adcal and cardio\u00adme\u00adta\u00adbo\u00adlic dise\u00ada\u00adses. With Euro\u00adpean produc\u00adtion capa\u00adci\u00adties and stable supply chains, PharOS is a stra\u00adte\u00adgic part\u00adner for leading phar\u00admaceu\u00adti\u00adcal compa\u00adnies. The company has a global port\u00adfo\u00adlio of over 100 products and more than 9,200 marke\u00adting autho\u00adriza\u00adti\u00adons. Drug shorta\u00adges are reaching histo\u00adric highs in the US, Europe and other markets due to a heavy reli\u00adance on phar\u00admaceu\u00adti\u00adcal products manu\u00adfac\u00adtu\u00adred in Asia. This depen\u00addence leads to fragile supply chains, which are further strai\u00adned by geopo\u00adli\u00adti\u00adcal tensi\u00adons and regu\u00adla\u00adtory chal\u00adlenges. Local produc\u00adtion is ther\u00ade\u00adfore of crucial stra\u00adte\u00adgic importance for Europe. Max Viess\u00admann, CEO of Viess\u00admann:<\/strong> \u201cOur entre\u00adpre\u00adneu\u00adrial acti\u00advi\u00adties are aimed at stra\u00adte\u00adgi\u00adcally promo\u00adting essen\u00adtial areas that are crucial for the well-being of future gene\u00adra\u00adti\u00adons. Gene\u00adrics are the foun\u00adda\u00adtion of afforda\u00adble global health\u00adcare. With our invest\u00adment in PharOS, we want to contri\u00adbute to a stable, inde\u00adpen\u00addent and resi\u00adli\u00adent Euro\u00adpean supply of afforda\u00adble and effec\u00adtive thera\u00adpies for life-threa\u00adtening diseases.\u201d <\/p>\n


\n<\/em><\/p>\n

Theo\u00addore Panag\u00ado\u00adpou\u00adlos, Part\u00adner at PharOS:<\/strong> \u201cWe are deligh\u00adted to have Viess\u00admann and Armira as new part\u00adners. Their long-term commit\u00adment to high-quality, afforda\u00adble and effec\u00adtive health\u00adcare solu\u00adti\u00adons fits perfectly with our own mission. Toge\u00adther, we are ideally posi\u00adtio\u00adned to further improve health\u00adcare world\u00adwide.\u201d PharOS is extre\u00admely well posi\u00adtio\u00adned to play a leading role in the multi-billion dollar market for oral solid gene\u00adrics, over-the-coun\u00adter medi\u00adci\u00adnes and value-added medi\u00adci\u00adnes. With a strong focus on inno\u00adva\u00adtion and rese\u00adarch, the company offers an end-to-end solu\u00adtion for complex products \u2014 from patent rese\u00adarch to dossier deve\u00adlo\u00adp\u00adment, appr\u00adoval and produc\u00adtion. In this way, PharOS crea\u00adtes added value for its custo\u00admers by proac\u00adtively contri\u00adbu\u00adting to the further deve\u00adlo\u00adp\u00adment of their product pipe\u00adline. PharOS employs around 400 people and is led by an expe\u00adri\u00aden\u00adced and dedi\u00adca\u00adted foun\u00adding team, which remains the majo\u00adrity shareholder.<\/p>\n

About Viess\u00admann Gene\u00adra\u00adti\u00adons Group<\/strong><\/p>\n

Foun\u00added in 1917, the inde\u00adpen\u00addent family-owned company Viess\u00admann is now a global, broadly diver\u00adsi\u00adfied group. All acti\u00advi\u00adties are based on the corpo\u00adrate mission state\u00adment \u201cWe create living spaces for future gene\u00adra\u00adti\u00adons\u201d \u2014 this is the passion and respon\u00adsi\u00adbi\u00adlity that drives the members of the large global Viess\u00admann family every day. In line with this goal, Viess\u00admann offers compa\u00adnies and co-crea\u00adtors an ecosys\u00adtem that is commit\u00adted to avoi\u00adding, redu\u00adcing and storing CO2 beyond the heating industry.<\/p>\n<\/div>\n

About Armira<\/strong><\/p>\n

\n

Armira is a leading Munich-based invest\u00adment holding company focu\u00adsed on direct invest\u00adments in mid-sized, profi\u00adta\u00adble family busi\u00adnesses and high-growth compa\u00adnies in the DACH region, Nort\u00adhern Italy and beyond. Armira is backed by an exclu\u00adsive circle of inves\u00adtors consis\u00adting of fami\u00adlies, entre\u00adpre\u00adneurs and entre\u00adpre\u00adneu\u00adrial capi\u00adtal to foster trus\u00adted part\u00adner\u00adships with a long-term focus. <\/p>\n

About PharOS<\/strong><\/p>\n

PharOS is a phar\u00admaceu\u00adti\u00adcal company specia\u00adli\u00adzing in the deve\u00adlo\u00adp\u00adment, manu\u00adfac\u00adture and supply of gene\u00adrics and value-added medi\u00adci\u00adnes. With a global port\u00adfo\u00adlio of over 100 products and more than 9,200 marke\u00adting autho\u00adriza\u00adti\u00adons world\u00adwide, PharOS is an important part\u00adner for the leading phar\u00admaceu\u00adti\u00adcal companies. <\/p>\n

Advi\u00adsor Armira: YPOG <\/strong><\/p>\n

Dr. Stephan Bank (Co-Lead, Corporate\/Structuring), Part\u00adner, Berlin Dr. Helder Schnitt\u00adker (Co-Lead, Tax\/Structuring), Part\u00adner, Berlin Jens Kretz\u00adschmann (Tax\/Structuring), Part\u00adner, Berlin\/Hamburg Lenn\u00adart Lorenz (Regu\u00adla\u00adtory), Part\u00adner, Hamburg.<\/p>\n

About YPOG<\/strong><\/p>\n

YPOG is a law firm specia\u00adli\u00adzing in tax and commer\u00adcial law, active in the core areas of funds, tax, banking + finance and tran\u00adsac\u00adtions. The YPOG team advi\u00adses a wide variety of clients. These include emer\u00adging tech\u00adno\u00adlogy compa\u00adnies and family-run medium-sized enter\u00adpri\u00adses as well as corpo\u00adra\u00adti\u00adons and private equity\/venture capi\u00adtal funds. YPOG is one of the leading addres\u00adses for venture capi\u00adtal, private equity and fund struc\u00adtu\u00adring in Germany. Today, YPOG employs more than 150 expe\u00adri\u00aden\u00adced lawy\u00aders, tax consul\u00adtants, tax specia\u00adlists and a notary in four offices in Berlin, Hamburg, Colo\u00adgne and Munich. www.ypog.law<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Munich\/ Batten\u00adberg (Eder) \u2014 Viess\u00admann Gene\u00adra\u00adti\u00adons Group (\u201cViess\u00admann\u201d), a leading family-owned company with a 107-year history, and the invest\u00adment holding Armira have acqui\u00adred a signi\u00adfi\u00adcant mino\u00adrity stake in the Euro\u00adpean phar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adper and manu\u00adfac\u00adtu\u00adrer PharOS as part of a consor\u00adtium. The invest\u00adment under\u00adlines Viess\u00adman\u00adn\u2019s stra\u00adte\u00adgic focus on long-term value crea\u00adtion in indus\u00adtries that are critical [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":52581,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366,1367,1369,1375],"tags":[],"class_list":["post-52583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-investors","category-family-offices-en"],"yoast_head":"\nArmira acquires minority stake in PharOS together with Viessmann - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"The Viessmann Generations Group, a leading family business with a 107-year history, and the investment holding Armira have acquired a significant minority stake in the European pharmaceutical developer and manufacturer PharOS as part of a consortium. The investment underlines Viessmann's strategic focus on long-term value creation in industries that are critical to the well-being of future generations. PharOS ensures access to high-quality and affordable healthcare in Europe. The Viessmann holding company now holds around 27 percent of the shares in the generics manufacturer, with Armira holding a further 13 percent.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Armira acquires minority stake in PharOS together with Viessmann - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"The Viessmann Generations Group, a leading family business with a 107-year history, and the investment holding Armira have acquired a significant minority stake in the European pharmaceutical developer and manufacturer PharOS as part of a consortium. The investment underlines Viessmann's strategic focus on long-term value creation in industries that are critical to the well-being of future generations. PharOS ensures access to high-quality and affordable healthcare in Europe. The Viessmann holding company now holds around 27 percent of the shares in the generics manufacturer, with Armira holding a further 13 percent.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-29T10:49:57+00:00\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Armira acquires minority stake in PharOS together with Viessmann\",\"datePublished\":\"2024-10-29T10:49:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\"},\"wordCount\":719,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif\",\"articleSection\":[\"General\",\"Featured\",\"Private equity\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Investors\",\"Family Offices\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\",\"url\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\",\"name\":\"Armira acquires minority stake in PharOS together with Viessmann - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif\",\"datePublished\":\"2024-10-29T10:49:57+00:00\",\"description\":\"The Viessmann Generations Group, a leading family business with a 107-year history, and the investment holding Armira have acquired a significant minority stake in the European pharmaceutical developer and manufacturer PharOS as part of a consortium. The investment underlines Viessmann's strategic focus on long-term value creation in industries that are critical to the well-being of future generations. PharOS ensures access to high-quality and affordable healthcare in Europe. The Viessmann holding company now holds around 27 percent of the shares in the generics manufacturer, with Armira holding a further 13 percent.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif\",\"width\":1280,\"height\":853},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Armira acquires minority stake in PharOS together with Viessmann\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Armira acquires minority stake in PharOS together with Viessmann - FYB Financial Yearbook","description":"The Viessmann Generations Group, a leading family business with a 107-year history, and the investment holding Armira have acquired a significant minority stake in the European pharmaceutical developer and manufacturer PharOS as part of a consortium. The investment underlines Viessmann's strategic focus on long-term value creation in industries that are critical to the well-being of future generations. PharOS ensures access to high-quality and affordable healthcare in Europe. The Viessmann holding company now holds around 27 percent of the shares in the generics manufacturer, with Armira holding a further 13 percent.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/","og_locale":"en_US","og_type":"article","og_title":"Armira acquires minority stake in PharOS together with Viessmann - FYB Financial Yearbook","og_description":"The Viessmann Generations Group, a leading family business with a 107-year history, and the investment holding Armira have acquired a significant minority stake in the European pharmaceutical developer and manufacturer PharOS as part of a consortium. The investment underlines Viessmann's strategic focus on long-term value creation in industries that are critical to the well-being of future generations. PharOS ensures access to high-quality and affordable healthcare in Europe. The Viessmann holding company now holds around 27 percent of the shares in the generics manufacturer, with Armira holding a further 13 percent.","og_url":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2024-10-29T10:49:57+00:00","author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Armira acquires minority stake in PharOS together with Viessmann","datePublished":"2024-10-29T10:49:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/"},"wordCount":719,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif","articleSection":["General","Featured","Private equity","News","Lawyers\/Tax-advisors\/Auditors","Investors","Family Offices"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/","url":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/","name":"Armira acquires minority stake in PharOS together with Viessmann - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif","datePublished":"2024-10-29T10:49:57+00:00","description":"The Viessmann Generations Group, a leading family business with a 107-year history, and the investment holding Armira have acquired a significant minority stake in the European pharmaceutical developer and manufacturer PharOS as part of a consortium. The investment underlines Viessmann's strategic focus on long-term value creation in industries that are critical to the well-being of future generations. PharOS ensures access to high-quality and affordable healthcare in Europe. The Viessmann holding company now holds around 27 percent of the shares in the generics manufacturer, with Armira holding a further 13 percent.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/10\/pharos-viessmann-armira-viessmann.avif","width":1280,"height":853},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/armira-acquires-minority-stake-in-pharos-together-with-viessmann\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Armira acquires minority stake in PharOS together with Viessmann"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=52583"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/52583\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/52581"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=52583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=52583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=52583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}